IMPAX LABORATORIES, INC. AND WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of June 30, 2015 2.00% Convertible Senior Notes due 2022Indenture • April 13th, 2018 • Atlas Holdings, Inc. • Pharmaceutical preparations • New York
INDENTURE dated as of June 30, 2015 between IMPAX LABORATORIES, INC., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and WILMINGTON TRUST, NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee,” as more fully set forth in Section 1.01).
RBC Capital Markets, LLC 3 World Financial Center 200 Vesey Street New York, New York 10281 Telephone: (212) 858-7000 June 26, 2015Atlas Holdings, Inc. • April 13th, 2018 • Pharmaceutical preparations
The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between Royal Bank of Canada (“Dealer”) and Impax Laboratories, Inc. (“Counterparty”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. This Confirmation shall replace any previous agreements and serve as the final documentation for the Transaction.
RBC Capital Markets, LLC 3 World Financial Center 200 Vesey Street New York, New York 10281 Telephone: (212) 858-7000 June 26, 2015Amneal Pharmaceuticals, Inc. • May 7th, 2018 • Pharmaceutical preparations
The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the Warrants issued by Impax Laboratories, Inc. (“Company”) to Royal Bank of Canada (“Dealer”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. This Confirmation shall replace any previous agreements and serve as the final documentation for the Transaction.
FORM OF AMNEAL PHARMACEUTICALS LLC THIRD AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT Dated as of [ ]Limited Liability Company Agreement • May 7th, 2018 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This THIRD AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT (this “Agreement”), dated as of [ ], is entered into by and among Amneal Pharmaceuticals LLC, a Delaware limited liability company (the “Company”), and its Members (as defined herein).
TAX RECEIVABLE AGREEMENT by and among AMNEAL PHARMACEUTICALS, INC. AMNEAL PHARMACEUTICALS LLC and THE MEMBERS OF AMNEAL PHARMACEUTICALS LLC FROM TIME TO TIME PARTY HERETO Dated as of [●]Tax Receivable Agreement • May 7th, 2018 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This TAX RECEIVABLE AGREEMENT (this “Agreement”), dated as of [●], is hereby entered into by and among Amneal Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), Amneal Pharmaceuticals LLC, a Delaware limited liability company (“Amneal LLC”) and each of the Members from time to time party hereto. Capitalized terms used but not otherwise defined herein have the respective meanings set forth in Section 1.1.
EMPLOYMENT AGREEMENTEmployment Agreement • April 13th, 2018 • Atlas Holdings, Inc. • Pharmaceutical preparations • Delaware
EMPLOYMENT AGREEMENT (“Agreement”), entered into as of December 12, 2012 (the “Effective Date”), by and between Impax Laboratories, Inc., a Delaware corporation (the “Company”), and Bryan M. Reasons (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • September 6th, 2022 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
This Employment Agreement (“Agreement”) is entered into as of September 1, 2022, by and between Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) and Gustavo Pesquin (the “Executive” and, collectively the “Parties”).
EMPLOYMENT AGREEMENTEmployment Agreement • May 7th, 2018 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
This EMPLOYMENT AGREEMENT (“Agreement”) is entered into as of May 4, 2018 (the “Effective Date”), by and between Amneal Pharmaceuticals, Inc. (“Amneal”) and Paul M. Bisaro (the “Executive”).
Execution Version AmericasActive:17030364.10 $350,000,000 REVOLVING CREDIT AGREEMENT, dated as of June 2, 2022, among AMNEAL PHARMACEUTICALS LLC, as the Borrower, THE LENDERS PARTY HERETO, TRUIST BANK as Administrative Agent and Collateral Agent,...Credit Agreement • June 2nd, 2022 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
AMENDMENT NO. 2 TO TERM LOAN CREDIT AGREEMENTTerm Loan Credit Agreement • November 14th, 2023 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
TERM LOAN CREDIT AGREEMENT, dated as of May 4, 2018 (as amended, amended and restated, supplemented or otherwise modified from time to time, this “Agreement”), by and among AMNEAL PHARMACEUTICALS LLC, a Delaware limited liability company (the “Borrower”), the Lenders party hereto from time to time and JPMORGAN CHASE BANK, N.A. (“JPM”), as administrative agent (in such capacity, and as further defined in Section 1.01, the “Administrative Agent”), and as collateral agent (in such capacity, and as further defined in Section 1.01, the “Collateral Agent”).
Execution Version US-DOCS\141444271.10 AMENDMENT NO. 1 TO TERM LOAN CREDIT AGREEMENT This AMENDMENT NO. 1 TO TERM LOAN CREDIT AGREEMENT, dated as of May 30, 2023 (this “Amendment No. 1”), is entered into by and among AMNEAL PHARMACEUTICALS LLC, a...Term Loan Credit Agreement • November 9th, 2023 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
EMPLOYMENT AGREEMENTEmployment Agreement • May 7th, 2021 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
This Employment Agreement (“Agreement”) is entered into as of July 29, 2020, by and among Amneal Pharmaceuticals, Inc. (the “Company”) and Nikita Shah (the “Executive” and, collectively with the Company, the “Parties”).
FIRST SUPPLEMENTAL INDENTURESupplemental Indenture • May 7th, 2018 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
FIRST SUPPLEMENTAL INDENTURE, dated as of November 6, 2017 (this “First Supplemental Indenture”), to the Indenture dated as of June 30, 2015 (the “Indenture”) between Impax Laboratories, Inc. (the “Company”), a Delaware corporation, and Wilmington Trust, National Association, a national banking association, as Trustee (the “Trustee”). Each term used herein which is defined in the Indenture has the meaning assigned to such term in the Indenture unless otherwise specifically defined herein, in which case the definition set forth herein shall govern.
FORM OF LETTER AGREEMENTLetter Agreement • August 5th, 2019 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This letter agreement (this “Letter Agreement”) is to confirm the mutual understanding among Credit Suisse AG, acting through its New York Branch (the “Lender”), Amneal Pharmaceuticals LLC (the “Company”), Amneal Pharmaceuticals, Inc. (“Amneal”) and __________ (the “Borrower”) with respect to the pledge (the “Pledge”) by the Borrower to the Lender (itself or through one of its affiliates, any such affiliate being treated as the Lender for purposes of this Letter Agreement) of, initially, _________ Units of the Company (the “Units”) and an equal number of shares of Class B Common Stock of Amneal (the “Class B Shares”), in each case pursuant to a Promissory Note and Collateral Agreement dated as of ____________ between the Borrower and the Lender (as amended, supplemented or modified from time to time, the “Loan Agreement”) and certain transactions related thereto. The Pledge will be made in favor of the Lender (the Units and Class B Shares that are so pledged at any time, the “Pledged S
TERMINATION AGREEMENT dated as of May 7, 2018 Between IMPAX LABORATORIES, LLC (f/k/a IMPAX LABORATORIES, INC.) and ROYAL BANK OF CANADATermination Agreement • May 7th, 2018 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS TERMINATION AGREEMENT (this “Agreement”) with respect to the Call Spread Confirmations (as defined below) is made as of May 7, 2018, between Impax Laboratories, LLC (formerly known as Impax Laboratories, Inc.) (“Company”) and Royal Bank of Canada (“Dealer”).
THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT DATED AS OF NOVEMBER 7, 2023 BY AND AMONG AMNEAL GROUP (AS DEFINED HEREIN), AMNEAL PHARMACEUTICALS LLC, AMNEAL INTERMEDIATE INC. AND AMNEAL PHARMACEUTICALS, INC.Stockholders Agreement • November 8th, 2023 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (as may be further amended from time to time in accordance with the terms hereof, this “Agreement”), is entered into as of November 7, 2023, by and among Amneal Pharmaceuticals, Inc., a Delaware corporation (formerly known as Amneal NewCo Inc.) (the “Company”), Amneal Intermediate Inc. (formerly known as Amneal Pharmaceuticals, Inc. and Atlas Holdings, Inc.), a Delaware corporation (“Old PubCo”), Amneal Pharmaceuticals LLC, a Delaware limited liability company (“Opco”) and each other Person set forth on the signature pages hereto (collectively, the “Amneal Group” and individually each, an “Amneal Group Member”).
REVOLVING CREDIT AND TERM LOAN AGREEMENT dated as of January 31, 2020 among RONDO INTERMEDIATE HOLDINGS, LLC as Borrower, RONDO HOLDINGS, LLC, as Holdings, THE LENDERS FROM TIME TO TIME PARTY HERETO, and TRUIST BANK as Administrative Agent SUNTRUST...Revolving Credit and Term Loan Agreement • February 4th, 2020 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS REVOLVING CREDIT AND TERM LOAN AGREEMENT (this “Agreement”) is made and entered into as of January 31, 2020, by and among RONDO INTERMEDIATE HOLDINGS, LLC, a Delaware limited liability company (the “Borrower”), RONDO HOLDINGS, LLC, a Delaware limited liability company (“Holdings”), several banks and other financial institutions and lenders from time to time party hereto (the “Lenders”) and TRUIST BANK, in its capacity as administrative agent for the Lenders (the “Administrative Agent”) and as issuing bank (the “Issuing Bank”).
MODIFICATION No. 2 to EMPLOYMENT AGREEMENT ENTERED FEBRUARY 6, 2018Employment Agreement • May 9th, 2023 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations
This Modification No. 2, dated as of February 21, 2023, and effective as of March 1, 2023, is made by and among Amneal Pharmaceuticals, Inc. (the “Company”) and Andrew Boyer (the “Executive” and, collectively with Amneal, the “Parties”).
TERM LOAN CREDIT AGREEMENT, dated as of November 14, 2023, among AMNEAL PHARMACEUTICALS LLC, as the Borrower, THE LENDERS PARTY HERETO, JPMORGAN CHASE BANK, N.A., as Administrative Agent and Collateral Agent, and JPMORGAN CHASE BANK, N.A., TRUIST...Credit Agreement • November 14th, 2023 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
TERM LOAN CREDIT AGREEMENT, dated as of November 14, 2023 (as amended, amended and restated, supplemented or otherwise modified from time to time, this “Agreement”), by and among AMNEAL PHARMACEUTICALS LLC, a Delaware limited liability company (the “Borrower”), the Lenders party hereto from time to time and JPMORGAN CHASE BANK, N.A. (“JPM”), as administrative agent (in such capacity, and as further defined in Section 1.01, the “Administrative Agent”), and as collateral agent (in such capacity, and as further defined in Section 1.01, the “Collateral Agent”).
AGREEMENT AND PLAN OF MERGER BY AND AMONG AMNEAL PHARMACEUTICALS, INC., AMNEAL NEWCO INC. AND AMNEAL MERGER SUB 1 INC. DATED AS OF NOVEMBER 7, 2023Agreement and Plan of Merger • November 8th, 2023 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This AGREEMENT AND PLAN OF MERGER (the “Agreement”) is entered into as of 12:01 a.m. Eastern Time on November 7, 2023, by and among Amneal Pharmaceuticals, Inc., a Delaware corporation (“Old PubCo”), Amneal NewCo Inc., a Delaware corporation and a direct, wholly owned subsidiary of Old PubCo (“New PubCo”), and Amneal Merger Sub 1 Inc., a Delaware corporation and a direct, wholly owned subsidiary of New PubCo (“Merger Sub 1”) (each a “Party” and collectively the “Parties”).
IN ACCORDANCE WITH THE SECURITIES AND EXCHANGE COMMISSION RULES, CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. BRACKETS WITH ASTERISKS...Share Purchase Agreement • March 1st, 2022 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations
AMNEAL PHARMACEUTICALS LLC FOURTH AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT Dated as of November 7, 2023Limited Liability Company Agreement • November 8th, 2023 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This FOURTH AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT (this “Agreement”), dated as of November 7, 2023, is entered into by and among Amneal Pharmaceuticals LLC, a Delaware limited liability company (the “Company”), and its Members (as defined herein).
EQUITY PURCHASE AGREEMENT among STEVE SHIRLEY BUSINESS TRUST, JERRY SHIRLEY BUSINESS TRUST, JERRY BRIAN SHIRLEY BUSINESS TRUST, DARREN THOMAS SHIRLEY BUSINESS TRUST, TROY MIZELL, DARRELL CALVERT, DIXON-SHANE LLC D/B/A R&S NORTHEAST LLC, AVKARE, INC....Equity Purchase Agreement • December 10th, 2019 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Equity Purchase Agreement (this “Agreement”), dated as of December 10, 2019, is entered into among the Jerry Brian Shirley Business Trust (the “JBS Trust”), the Darren Thomas Shirley Business Trust (the “DTS Trust”), the Steve Shirley Business Trust (the “SS Trust”), the Jerry Shirley Business Trust (the “JS Trust”, and collectively with the JBS Trust, the DTS Trust, the SS Trust, the “Trusts”), Troy Mizell, a resident of the State of Tennessee (“Mizell”), Darrell Calvert, a resident of the Commonwealth of Kentucky (“Calvert”) (the Trusts, Mizell and Calvert each being a “Seller” and collectively being the “Sellers”), AvKARE, Inc., a Tennessee corporation (“AvKARE”), Dixon-Shane, LLC d/b/a R&S Northeast LLC, a Kentucky limited liability company (“R&S Northeast”, and together with AvKARE, each a “Company” and collectively, the “Companies”), and Rondo Acquisition LLC, a Delaware limited liability company (“Buyer”). Steve Shirley also joins this Agreement in his capacity as the Selle
Term Sheet Amneal Pharmaceuticals, Inc.Amneal Pharmaceuticals, Inc. • October 17th, 2023 • Pharmaceutical preparations • Delaware
This Term Sheet (the “Term Sheet”) is entered into as of October 16, 2023, by and among Amneal Pharmaceuticals, Inc., a Delaware corporation (“Old PubCo”), Amneal Pharmaceuticals LLC (“Opco”) and, solely for purposes of the Amneal Group Representative Consent (as defined below), the Amneal Group Representative1, on behalf of the Amneal Legacy Group. Each of Old PubCo and Opco may be referred to herein as a “Party” and collectively as the “Parties”.
ContractCredit and Term Loan Agreement • November 9th, 2023 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
AMENDMENT NO. 1 TO THIRD AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT OF AMNEAL PHARMACEUTICALS LLCAmneal Pharmaceuticals, Inc. • March 1st, 2019 • Pharmaceutical preparations • Delaware
This Amendment No. 1 to the Third Amended and Restated Limited Liability Company Agreement of Amneal Pharmaceuticals LLC (this “Amendment”), dated as of February 14, 2019, with effect as of May 4, 2018, is entered into by and among Amneal Pharmaceuticals LLC (the “Company”), the Manager and the Members set forth on the signature pages hereto.
MODIFICATION No. 2 to EMPLOYMENT AGREEMENT ENTERED MARCH 11, 2020Employment Agreement • May 9th, 2023 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations
This Modification No. 2, dated as of February 21, 2023, and effective as of March 1, 2023, is made by and among Amneal Pharmaceuticals, Inc. (the “Company”) and Anastasios G. Konidaris (the “Executive” and, collectively with Amneal, the “Parties”).
AGREEMENT AND PLAN OF MERGER BY AND AMONG AMNEAL PHARMACEUTICALS, INC., AMNEAL PHARMACEUTICALS LLC AND AMNEAL MERGER SUB 2 LLC DATED AS OF NOVEMBER 7, 2023Agreement and Plan of Merger • November 8th, 2023 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This FOURTH AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT (this “Agreement”), dated as of November 7, 2023, is entered into by and among Amneal Pharmaceuticals LLC, a Delaware limited liability company (the “Company”), and its Members (as defined herein).
AMNEAL PHARMACEUTICALS, INC. STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENTStock Option Agreement • May 7th, 2018 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Amneal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), pursuant to its 2018 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”) an option to purchase the number of Shares set forth below (the “Option”). The Option is subject to the terms and conditions set forth in this Stock Option Grant Notice (the “Grant Notice”), the Stock Option Agreement attached hereto as Exhibit A (the “Agreement”), the Plan and the special provisions for Participant’s country of residence, if any, attached hereto as Exhibit B (the “Foreign Appendix”), each of which is incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Grant Notice and the Agreement.
Re: Notice of Employment Termination Dear Todd:Amneal Pharmaceuticals, Inc. • May 11th, 2020 • Pharmaceutical preparations
Amneal Pharmaceuticals, Inc. (together, "Amneal") dated January 21, 2019 (your "Employment Agreement"). Your status as an officer of Amneal ends effective as of today, March 11, 2020, and you are hereby relieved of all of your duties and responsibilities related to your officer position. Your employment with Amneal will continue until March 31, 2020 (the "Termination Date"), and this letter constitutes notice under Section 4.1.6 of your Employment Agreement that your employment with Amneal will terminate without cause effective as of the Termination Date.
PURCHASE AND SALE AGREEMENT by and among AMNEAL PHARMACEUTICALS LLC, GEMINI LABORATORIES, LLC, THE PERSONS SIGNATORY HERETO AS SELLERS AND THE SELLERS’ REPRESENTATIVE Dated as of May 7, 2018Purchase and Sale Agreement • May 7th, 2018 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Purchase and Sale Agreement, dated as of May 7, 2018 (this “Agreement”), by and among (i) Amneal Pharmaceuticals LLC, a Delaware limited liability company (the “Buyer”), (ii) Gemini Laboratories, LLC, a Delaware limited liability company (the “Acquired Company” or “Gemini”), (iii) each of the persons designated on the signature pages hereto as Sellers (each a “Seller” and, collectively, the “Sellers”), and (iv) Vikram Patel, solely in his capacity as the Sellers’ Representative.
Amendment No. 1 to the Second Amended and Restated Stockholders AgreementStockholders Agreement • August 5th, 2019 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Amendment No. 1 (this “Amendment”) to the Second Amended and Restated Stockholders Agreement dated as of December 16, 2017 (the “Agreement”), by and among Amneal Pharmaceuticals Holding Company, LLC, a Delaware limited liability company, AP Class D Member, LLC, a Delaware limited liability company, AP Class E Member, LLC, a Delaware limited liability company, AH PPU Management, LLC, a Delaware limited liability company, and Amneal Pharmaceuticals, Inc. (which was previously known as Atlas Holdings, Inc.), a Delaware corporation, is entered into as of this 2nd day of August, 2019. Capitalized terms used in this Amendment and not otherwise defined shall have the meanings ascribed to them in the Agreement.
ASSET PURCHASE AGREEMENT AMONG SAOL INTERNATIONAL LIMITED, SAOL THERAPEUTICS RESEARCH LIMITED, SAOL THERAPEUTICS INC., SAOL INTERNATIONAL RESEARCH LIMITED, SAOL INTERNATIONAL DEVELOPMENT LIMITED, EMERALD INTERNATIONAL LIMITED, EMERALD THERAPEUTICS...Asset Purchase Agreement • January 5th, 2022 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Asset Purchase Agreement (this “Agreement”) is entered into as of December 30, 2021, by and among Saol International Limited, a Bermuda limited company (“SIL”), Saol Therapeutics Research Limited, an Irish limited company (“STRL”), Saol Therapeutics Inc., a Delaware corporation (“STI”), Saol International Research Limited, a Bermuda limited company (“SIRL”), Saol International Development Limited, a Bermuda limited company (“SIDL”), Emerald International Limited, a Bermuda limited company (“Emerald”), Emerald Therapeutics Research Limited, an Irish limited company (“ETRL” and, collectively with SIL, STRL, STI, SIRL, SIDL and Emerald, “Sellers” and each, individually, a “Seller”), and Amneal Pharmaceuticals LLC, a Delaware limited liability company (“Buyer”). Buyer and Sellers are each referred to herein as a “Party” and collectively herein as the “Parties.”
SEPARATION AGREEMENTSeparation Agreement • August 5th, 2019 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • Florida
This Separation Agreement (“Separation Agreement”) is entered into between Robert Stewart (“Executive”) and Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals, Inc. (f/k/a Atlas Holdings, Inc.) (collectively “Amneal” or the “Company”) as of August 2, 2019 (the “Effective Date”). Capitalized terms not otherwise defined herein shall have the meanings set forth in that certain Employment Agreement between Executive and the Company entered into as of December 16, 2017 (“Employment Agreement”) as amended from time to time.
TERM LOAN GUARANTEE AND COLLATERAL AGREEMENT, dated as of May 4, 2018, among AMNEAL PHARMACEUTICALS LLC, as the Borrower, each other Grantor party hereto, and JPMORGAN CHASE BANK, N.A., as Administrative Agent and Collateral AgentExecution Version • May 7th, 2018 • Amneal Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
TERM LOAN GUARANTEE AND COLLATERAL AGREEMENT dated as of May 4, 2018 (as amended, amended and restated, supplemented or otherwise modified from time to time, this “Agreement”), among AMNEAL PHARMACEUTICALS LLC (the “Borrower”) and each other party identified as a “Grantor” on the signature pages hereto (together with any other entity that may become a party hereto as a Grantor as provided herein, each a “Grantor” and, collectively, the “Grantors”), and JPMORGAN CHASE BANK, N.A. (“JPM”), as Administrative Agent for the Lenders under the Credit Agreement referred to below (in such capacity, the “Administrative Agent”) and as Collateral Agent for the Secured Parties (as defined below) (in such capacity, the “Collateral Agent”).
